Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells $65,229.12 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 18,531 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $3.52, for a total value of $65,229.12. Following the transaction, the insider owned 52,274 shares of the company’s stock, valued at approximately $184,004.48. The trade was a 26.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.33, for a total value of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Trading Down 11.0%

Shares of SHPH stock traded down $0.36 on Friday, reaching $2.92. The company’s stock had a trading volume of 67,573 shares, compared to its average volume of 2,340,694. The stock’s fifty day simple moving average is $5.01 and its 200-day simple moving average is $10.13. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90. The company has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.06 and a beta of 0.29.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter worth about $357,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter worth about $124,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

SHPH has been the topic of a number of research reports. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .